ArticleCurrent medical imaging2025
Predicting Chronic Liver Disease Severity by Liver and Splenic Extracellular Volume Fraction Derived from spectral-CT.
Article in Current medical imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionTo evaluate the effectiveness of spectral-CT in assessing the severity of liver diseases in patients with chronic liver disease (CLD).
methodsA total of 148 CLD patients who underwent spectral-CT were retrospectively recruited, including 40 non-advanced CLD (non-ACLD), 74 compensated ACLD (cACLD), and 34 decompensated ACLD (dACLD). Iodine concentrations in the liver and spleen were assessed on iodine (water) images during the equilibrium phase, which allowed for the calculation of liver and splenic extracellular volume fractions (ECV). We determined the total liver volume, liver segmental volume ratio, and splenic volume from portal phase images. Moreover, established non-invasive tests were also collected. Areas under receiver operating characteristic curve (AUCs) were employed to evaluate the diagnostic performance of CT parameters and non-invasive tests in predicting CLD severity. Additionally, we analyzed the correlations between CT parameters and non-invasive tests.
resultsThe spleen volume demonstrated the highest AUC (0.815, P<0.001) for distinguishing between non-ACLD and cALCD. Child-Pugh score exhibited the highest AUC (0.948, P<0.001) for distinguishing cALCD and dACLD. Splenic ECV exhibited the highest AUC (0.853, P<0.001) for distinguishing non-ALCD and ACLD. In contrast, the liver ECV showed strong correlations with the Fibrosis-4 Index (r=0.653, p<0.001) and the Aminotransferase-to-Platelet Ratio Index (r=0.607, p<0.001), while spleen ECV correlated more strongly with the Child-Pugh score (r=0.719, p<0.001) and the Albumin-Bilirubin Index (r=0.742, p<0.001). DISCUSSION: Liver and splenic ECV can effectively reflect the dynamic progression of CLD and correlate well with non-invasive tests in these patients.
conclusionSpectral-CT liver and splenic ECV could serve as non-invasive imaging biomarkers for severity stratification.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.